medigraphic.com
ISSN 0188-2198 (Impreso)

2005, Número 1

<< Anterior Siguiente >>

Rev Mex Cardiol 2005; 16 (1)


Tratamiento

Cardona MEG, Carranza MJ, Hernández HH

Idioma: Español
Referencias bibliográficas: 56
Paginas: 19-27
Archivo PDF: 63.98 Kb.


FRAGMENTO

OBJETIVO DEL TRATAMIENTO

El objetivo es evitar la expresión de la enfermedad, reducir las complicaciones causadas por ella, con incremento en la duración y calidad de la vida. Aunque el mayor beneficio sobre la reducción del riesgo relativo se obtiene con el logro de las metas de presión arterial, se requiere ver al individuo como un todo e intervenir en forma global los factores de riesgo y las enfermedades coexistentes para obtener el máximo beneficio.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension. Journal of Hypertension 2003; 21: 1011-1053.

  2. He J, Whelton PK. What is the role of dietary sodium and potassium and hypertension and target organ injury? Am J Med Sci 1999; 317: 152-159.

  3. Whelton PK, Appel IJ, Espeland MA. Sodium Reduction and weight loss in the treatment of hypertension in older people: a randomized controlled trial of non-pharmacologic intervention in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279: 839-846.

  4. He J, Whelton PK, Appel IJ. Long-Term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000; 35: 544-549.

  5. Leiter LA, Abbott D, Campbell NRC. A recommendation on obesity and weight loss. CMAJ 1999; 160(Suppl 9): S7-S11.

  6. Stevens VJ, Obarzanek E, Cook NR, Lee IM. Long-term weight loss and changes in results of the Trials of Hypertension Prevention, Phase II. Ann Intern Med 2001; 134: 1-11.

  7. Sacks FM, Svetkey LP, Vollmer WM. For the DASH-Sodium Collaborative Research Group. Effects of blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10.

  8. Margwetts BM, Beilin MJ, Vandongen R, Armstrong BK. Vegetarian diet in mild hypertension: a randomized controlled trial. BMJ 1986; 293: 1468-1473.

  9. Hagberg JM, Park JJ, Brown MD. The role of exercise training in the treatment of hypertension: An update Sport Med 2000; 30: 193-206.

  10. Fagard RH. Exercise characteristics and the blood pressure response to dynamic physical training. Med Sci Sports and Exerc 2001; 33(Suppl): S484-S492.

  11. Chobanian AV, Hill M. National Heart, Lung and Blood Institute Workshop on Sodium and Blood Pressure: a critical review of current scientific evidence. Hypertension 2000; 35: 858-863.

  12. Volver WM, Sacks FM, Ard J. Effects of diet and sodium intake on blood pressure. Ann Intern Med 2001; 135: 1019-1028.

  13. Xin X, He J, Frontini MG, Ogden LJ. Effects of alcohol reduction on blood pressure. A meta-analysis of randomized controlled trials. Hypertension 2001; 38: 1112-1117.

  14. Hansson L, Zanchetti A, Carruthers SG et al, for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principals results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.

  15. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-Stage renal disease in African-american and white men: 16-year MRFIT findings. JAMA 1997; 277: 1293-1298.

  16. Lazarus JM, Bourgoignie JJ, Buckalew VM et al, for the Modification of Diet in Renal Disease Study Group. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29: 641-650.

  17. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type 2 diabetes mellitus: what guidance for recent randomized controlled trials? J Hypertens 2002; 20: 2099-2110.

  18. National Kidney Foundation Guidelines. K/DOQ1 clinical practice guidelines for chronic kidney disease: Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis 2002; 39(Suppl 2): S1-S24.

  19. Hansson L, Zanchetti A. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension. Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.

  20. World Health Organization. The World Health Report 2002: Risk to Health 2002 Geneva: World Health Organization.

  21. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Death from Cardiovascular Causes, Myocardial infarction, and Stroke in High-Risk Patients. N Engl J of Medicine 2000; 342: 145-153.

  22. Lindholm LH, Ibsen H, Borch-Johnsen K. Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-1886.

  23. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T et al. Outcomes with nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-436.

  24. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.

  25. Brown MJ. Implications from hypertension outcome trials for the management of patients with hypertension and diabetes. Br J Diabetes Vasc Dis 2003; 3: 245-251.

  26. Hansson L, Lindholm LH, Niskanen L et al, for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611-616.

  27. Wright JT Jr, Agodoa L, Contreras G. Successful blood pressure control in the african-american Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162: 1636-1642.

  28. Lewis EJ, Hunsicker LG, Clarke WR. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Tipe-2 diabetes. N Engl J Med 2001; 345: 851-860.

  29. Brenner BM, Cooper ME. From the REENAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.

  30. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy, Lancet 2000; 355: 253-259.

  31. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with Type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20: 2099-2110.

  32. Marre M, Fernández M, García-Puig J, Halabe A, Hermansen K, Ionescu-Tirgoviste C, Jermendy G et al on behalf of the Investigators; NESTOR Study Group. Value of Natrilix SR in Hypertensive Type 2 diabetics patients with microalbuminuria. J Hypertension 2002; 20(S4): S338.

  33. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.

  34. Flather MD, Yusuf S, Kober L, Pffefer M. Long term ACE-inhibitors therapy in patients with heart failure or left ventricular dysfunction. A systematic overview of data for individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-1581.

  35. Pitt B, Poole-Wilson PA, Segal R. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.

  36. Gottdiener JS, Reda DJ, Massie BM, Matterson BJ, for the Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1997; 95: 2007-2014.

  37. Debereux RV, Palmieri V, Sharpe N. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001; 104: 1248-1254.

  38. Cuspide C, Muiesan ML, Valagussa L, on behalf of the CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-2300.

  39. Dahlöf B, Zanchetti A, Diez J, Nicholls MG. Effects of Losartan and Atenolol on left ventricular mass and neurohormonal profile and patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20: 1855-1864.

  40. Lindholm LH, Ibsen H, Dahlöf B, Debereux RV. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for endpoint reduction in hypertension study (LIFE). A randomized trial against Atenolol. Lancet 2002; 359: 1004-1010.

  41. Gosse P, Dubourg O, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg the LIVE study. J Hypertens 2000; 18: 1465-1475

  42. Freemantle N, Cleland J, Young P. b-Blockade after myocardial infarction. Systematic review and regression analysis. BMJ 1999; 318: 1730-1737.

  43. Doughty R, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 1997; 18: 560-565.

  44. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988; 9: 8-16.

  45. The MERIT-HF investigators. Effect of metoprotol CR/XL in chronic heart failure: Metoprotol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.

  46. The CIBIS-II investigators. The Cardiac Insufficiency Bisoprostol Study II. (CIBIS-II): a randomized trial. Lancet 1999; 353: 9-13.

  47. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357: 1385-90.

  48. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatments in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.

  49. Tuomilehto J, Rastenyte D, Birkenhäger WH et al. For the Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-684.

  50. Staessen J, Wong JG. Benefit of antihypertensive drug treatment in older patients with isolated systolic hypertension. Eur Heart J 1999; Suppl 1(SP): P3-P8.

  51. Emeriau JP, Knauf H, Ocon Pujadas J, Callvo-Gomez C, Abate G, Leonetti G, Chastang C, on behalf of the European Study Investigators. A comparison of indapamida SR 1.5 mg with both amlodipino 5 mg and hydroclorothiazide 25 mg in elderly hypertensive patients a randomized double-blind controlled study. J Hypertens 2001; 19(2): 343-350.

  52. WHO/ISH statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.

  53. Amery A, Birkenhäger WH, Bulpitt CJ, Dollery CT. European Working Party on High blood pressure in the Elderly. Am J Med 1991-90; (Suppl 3): 1S-64S.

  54. Staessen JA, Fagard R, Thijs L et al. Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med 1998; 158: 1681-1691.

  55. Wang JG, Liu G, Wang X, Zhang S, Sun M, Pan X, Jian M, Gong L, Thijs L, Staessen J, Fagard R, Liu L. Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial. J Hum Hypertens 1996; 10: 735-742.

  56. Leonetti G. Clinical positioning of Indapamide Sustained Release 1.5 mg in Management Protocols for Hypertension. Drugs. 2000; 59(S2): 27-38.




2020     |     www.medigraphic.com